603309 reported revenue of ¥0.77B for the period ended 2026-06-30, +3.2% year on year. Net income was ¥0.11B, a 14.0% net margin on a 43.3% gross margin. The largest revenue line is 麻醉 at 30% of the total.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.77B | +3.2% |
| Gross profit | ¥0.33B | — |
| Operating income | ¥0.13B | — |
| Net income | ¥0.11B | -15.0% |
| Gross margin | 43.3% | Net margin 14.0% |
| Revenue Q/Q | +15.4% | — |
| Segment | Revenue | Share |
|---|---|---|
| 麻醉 | ¥0.23B | 29.9% |
| 导尿 | ¥0.22B | 28.1% |
| 泌尿外科 | ¥0.13B | 16.5% |
| 护理 | ¥0.09B | 11.2% |
| 血透 | ¥0.04B | 5.6% |
| 呼吸 | ¥0.03B | 4.0% |
| 其他(补充) | ¥0.03B | 3.4% |
| 其他主营业务 | ¥0.01B | 1.3% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.44B | 56.7% |
| R&D | ¥0.05B | 6.3% |
| SG&A | ¥0.13B | 17.2% |
| Tax & other | ¥0.02B | 2.7% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
万科A ・ 中兴通讯 ・ TCL科技 ・ 中联重科 ・ 申万宏源 ・ 东方盛虹 ・ 美的集团 ・ 潍柴动力 ・ 藏格矿业 ・ 徐工机械 ・ 云南白药 ・ 泸州老窖
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies